Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (141-150 of 274) with videos related to

Pageof 28
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myelomaSusann Szmania, Sacha Gnjatic, Guido Tricot, et al.
Blood|April 25, 2009
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBijay Nair, John D Shaughnessy, Yiming Zhou, et al.
Plos One|September 26, 2013
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myelomaBo Hu, Yu Chen, Saad Z Usmani, et al.
Bone|February 8, 2021
Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experienceMeera Mohan, Manoj Kumar, Rohan Samant, et al.
Experimental Hematology|January 25, 2003
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioningChoon Kee Lee, Ashraf Badros, Bart Barlogie, et al.
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
Blood Cancer Journal|March 31, 2026
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patientsHira Cheema, Asis Shrestha, Syed Naqvi, et al.
Haematologica|June 27, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling dataSarah Waheed, Alan Mitchell, Saad Usmani, et al.
Blood|June 8, 2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceSaad Z Usmani, Rachel Sexton, Antje Hoering, et al.
British Journal of Haematology|May 11, 2007
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular geneticsJohn D Shaughnessy, Jeffrey Haessler, Frits van Rhee, et al.
Pageof 28

Showing results (141-150 of 274) with videos related to

Sort By:
Pageof 28
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myelomaSusann Szmania, Sacha Gnjatic, Guido Tricot, et al.
Blood|April 25, 2009
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBijay Nair, John D Shaughnessy, Yiming Zhou, et al.
Plos One|September 26, 2013
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myelomaBo Hu, Yu Chen, Saad Z Usmani, et al.
Bone|February 8, 2021
Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experienceMeera Mohan, Manoj Kumar, Rohan Samant, et al.
Experimental Hematology|January 25, 2003
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioningChoon Kee Lee, Ashraf Badros, Bart Barlogie, et al.
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
Blood Cancer Journal|March 31, 2026
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patientsHira Cheema, Asis Shrestha, Syed Naqvi, et al.
Haematologica|June 27, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling dataSarah Waheed, Alan Mitchell, Saad Usmani, et al.
Blood|June 8, 2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceSaad Z Usmani, Rachel Sexton, Antje Hoering, et al.
British Journal of Haematology|May 11, 2007
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular geneticsJohn D Shaughnessy, Jeffrey Haessler, Frits van Rhee, et al.
Pageof 28